EYEG - Eyegate Pharmac Charts, Trade Ideas, Earnings, Ratings

TRENDING : Top 50 SPY (-3.03%) AAPL (-3.39%) FB (-1.97%) GNPX (3.32%) AMD (-3.16%) ALGN (-4.38%) NVDA (-4.11%) SPCE (-0.73%) V (-5.23%) VXX (9.46%) XEC (-7.95%) HEXO (-3.82%) HAL (-4.14%) GRPN (-4.49%) ACB (-2.59%) GILD (-3.85%) FNV (-1.94%) FDX (-5.98%) EEM (-0.8%) DXC (-7%) DIS (-3.63%) DGAZ (1.3%) CRON (-5.34%) CNC (-5.73%) CME (-0.47%)

Down 10% to $5.80 today

EYEG - Eyegate Pharmaceutic...

$6.04 -0.79[-11.45%]

15 mins delayed data

People also watch : SNOA | MYOS | KALV | FLKS

+Watchlist

4 StockHoot Traders following this.
Analyst Ratings | Earnings

Previous Close	$6.82	Open	$6.71
Volume	100.5K	Market Cap	13.22M
Yield		Last Dividend

Day

52 Week

EyeGate Pharmaceuticals : December 31, 2...	12/31/19
EyeGate Pharmaceuticals, Inc. , a clinical-stage company focused on developing products for treating disorders of the eye, today announced that it has...

EyeGate Pharma (EYEG) Has Caught Investo...	12/31/19
Shares of EyeGate Pharmaceuticals Inc. (EYEG), which closed at a new 52-week high of $12.20 on Monday, have gained an impressive 312% in the last thre...

EyeGate Pharmaceuticals : December 17, 2...	12/17/19
EyeGate Pharmaceuticals, Inc. announced today that it has received approximately $1.9 million from the exercise of warrants subsequent to the release ...

EyeGate Pharma Receives $1.9 Million fro...	12/17/19
The Company is currently evaluating several strategic options in order to determine the best path forward. Following the receipt of warrant exercise p...

EyeGate Pharma Announces Additional Posi...	12/02/19
As previously announced, the results of this pivotal study demonstrated statistically significant improvement in corneal re-epithelialization in patie...

EyeGate shares jump on data for eye trea...	11/22/19
Shares of EyeGate Pharmaceuticals Inc. rallied 95% in premarket trading on the news that the company's experimental eye-drop bandage performed better ...

EyeGate Pharma Receives Positive Nasdaq ...	05/14/19
WALTHAM, MA / ACCESSWIRE / May 14, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company") today announced that the Nasdaq Hearings P...

Eyegate Pharmaceuticals beats by $0.06	05/08/19
No summary available.

EyeGate files for $50M mixed shelf	05/03/19
EyeGate Pharmaceuticals (EYEG) has filed a preliminary prospectus for a $50M mixed shelf offering.

The Daily Biotech Pulse: FDA Nod For San...	05/02/19
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 1) Al...

EyeGate Files IDE with FDA for PRK Pivot...	05/02/19
WALTHAM, MA / ACCESSWIRE / May 2, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) (''EyeGate'' or ''the Company'') announced today it has successfully sub...

EyeGate confirms path to de novo filing ...	03/26/19
No summary available.

EyeGate Confirms Path to De Novo Filing ...	03/26/19
WALTHAM, MA / ACCESSWIRE / March 26, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company") has met with the U.S. Food and Drug Admi...

EyeGate Pharma books $1.7M in revenue in...	03/01/19
No summary available.

Eyegate Pharmaceuticals reports FY resul...	03/01/19
No summary available.

EyeGate Pharma to meet with FDA	01/16/19
No summary available.

EyeGate Pharma to meet with FDA	01/16/19
No summary available.

ANALYST RATINGS

0 analyst ratings (Last 6 months)

0.00 %

Strong Buy + Buy

Price Target (PT)

EARNINGS

Date	04/12/2019 (AMC)	Est. (EPS/Rev.)	$1.37
Actual (EPS/Rev.)	$2.5B	EPS (TTM)	$???

TRADERS TRACKING $EYEG

Service Name	Trader	% Success
Tech Trades	Ravi	90.00 %	Follow
Mojo Day Trading	ProTrader Mike	46.00 %	Subscribe
Biotechnology	Robert Gadimian	26.00 %	Follow

SHOW ALL TRADERS

About Us

Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.

Product Types

Strategies

Follow Us

Secure Payments

We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.